A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid (Q33586505)

28 July 2017

title

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid (English)

1 reference

28 July 2017

main subject

phase II clinical trial

0 references

Chitra M Hosing

11

0 references

Robert Z Orlowski

series ordinal

4

object named as

Robert Z Orlowski

1 reference

28 July 2017

13

Sergio A Giralt

1 reference

28 July 2017

12

Uday R Popat

1 reference

28 July 2017

14

Richard E Champlin

1 reference

28 July 2017

5

Roland L Bassett

1 reference

28 July 2017

3

Peter F Thall

1 reference

28 July 2017

8

Simrit Parmar

1 reference

28 July 2017

15

Muzaffar H Qazilbash

1 reference

28 July 2017

7

Qaiser Bashir

1 reference

28 July 2017

6

Nina Shah

1 reference

28 July 2017

10

Jatin J Shah

1 reference

28 July 2017

Manish Sharma

1

1 reference

28 July 2017

Hassan Khan

series ordinal

2

1 reference

28 July 2017

Michael Wang

series ordinal

9

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 September 2011

1 reference

28 July 2017

1 reference

28 July 2017

volume

118

1 reference

28 July 2017

issue

9

1 reference

28 July 2017

page(s)

2507-2515

1 reference

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

Treatment of multiple myeloma: a comprehensive review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

International uniform response criteria for multiple myeloma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

Evaluation of survival data and two new rank order statistics arising in its consideration

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 June 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26517

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26517

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26517

In the age of novel therapies, what defines high-risk multiple myeloma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26517

On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26517

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26517

Estimating the Dimension of a Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26517

Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26517

Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26517

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015116

HyperCVAD for VAD-resistant multiple myeloma

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21887685

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21887685

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bayesian Survival Analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26517

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.26517

1 reference

28 July 2017

1 reference

28 July 2017

1 reference